On August 11, 2025, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (referred to as “ImmuneOnco,” with the stock code 01541.HK on the Hong Kong Stock Exchange) announced that it will present the Phase I clinical study results of Peviplamab (IMM2510) in advanced squamous non-small cell lung cancer (SQ-NSCLC) post-immune therapy at the 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain, from September 6 to 9, in the form of a poster presentation.

The abstract information for ImmuneOnco’s Peviplamab (IMM2510) selected for the 2025 WCLC is as follows:

IMM2510, an Anti-PD-L1/VEGF Bispecific Antibody Fusion Protein for Advanced IO-treated SQ-NSCLC: A Phase I Study

PD-L1xVEGF Bispecific Antibody IMM2510 for Advanced SQ-NSCLC Post-Immune Therapy: A Phase I Clinical Study

• Presentation Format: Poster Presentation

• Abstract Number: 4792

• Session: P3.12 - Metastatic Non-Small Cell Lung Cancer - Targeted Therapy

• Date: September 9, 2025 (Tuesday)

• Presentation Time: 10:00 AM - 11:30 AM

Clinical Trial Updates

• The Phase I clinical study of IMM2510 in Chinese patients with solid tumors has shown positive efficacy signals and good safety, especially in patients with squamous non-small cell lung cancer (SQ-NSCLC) who had previously failed treatment with PD-1 or PD-L1 inhibitors. These results will be presented at the 2025 World Conference on Lung Cancer (WCLC).

• The Phase II clinical trial of IMM2510 in combination with chemotherapy for first-line treatment of non-small cell lung cancer (NSCLC) is recruiting patients smoothly in China. As of July 1, 2025, the overall best objective response rate (ORR) in the evaluable population was 62%, with an ORR of 80% in patients with squamous NSCLC. The safety of this therapy is tolerable and controllable, supporting further clinical development. Plans are underway to initiate a Phase III clinical trial. More relevant research results will be published at future international academic conferences.

• A Phase I clinical trial of IMM2510 monotherapy for recurrent/refractory solid tumors is scheduled to be launched in the United States in the second half of 2025.

(The above Phase II clinical data for IMM2510 in combination with chemotherapy for first-line treatment of non-small cell lung cancer (NSCLC) has been previously disclosed by the company and will not be presented at this WCLC; the detailed content of the poster abstract will be displayed at the conference.)

Statement from ImmuneOnco’s Founder, Chairman, CEO, and CSO

Dr. Tian Wenzhi, Founder, Chairman, CEO, and CSO of ImmuneOnco, stated:

“We are very pleased that the clinical study of IMM2510 has been selected for poster presentation at the 2025 WCLC. This is not only a recognition of the potential of IMM2510 but also an affirmation of our team’s commitment to innovation and relentless efforts over the years. We have always believed that science-driven innovative research and development can bring more effective treatment options to patients. Moving forward, we will continue to advance the clinical studies of IMM2510, explore its application potential in more indications, and bring more hope to cancer patients worldwide.”

Statement from ImmuneOnco’s Chief Medical Officer

Dr. Wu Zhuli, Chief Medical Officer of ImmuneOnco, stated:

“The monotherapy of IMM2510 in patients with advanced squamous non-small cell lung cancer who have failed immune therapy has shown encouraging clinical efficacy and manageable safety. Additionally, the combination of IMM2510 and chemotherapy has demonstrated positive clinical efficacy signals in first-line NSCLC. We will spare no effort in accelerating the clinical development of IMM2510 and look forward to it becoming a new treatment option for a broad range of cancer patients in the future.”